Numares. |Precision Diagnostics.

2

Locations: Houston, Texas;
Regensburg, Germany

2004

Founded as a spin-off of
Regensburg University, Regensburg, Germany

3.5 M

Tests performed globally

Mastering Metabolic Constellations. |For Precision Diagnostics.

Numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet health care needs not addressed by single biomarker-based medicine.

Our diagnostic tests are based on the interpretation of multiple biomarkers that precisely pinpoint relevant data related to organ function. With these next-generation metabolite constellations, we develop non-invasive diagnostic tests designed to provide more precise information than the current standard tests.

Meilensteine des Unternehmens

2021

Exclusive license agreement with Oxford University

2021

FDA 510(k) submission for the AXINON^®System, an NMR platform for metabolomics-based, AI-driven diagnostics

2021

numares and Bruker Corporation sign agreement to enable advanced metabolomics-based clinical diagnostics

2019

Numares begins strategic collaboration with Mayo Clinic Laboratories to develop new diagnostic tests

2018

numares completes another financing round

2018

Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection

2017

Launch of AXINON^® renalTX-SCORE^®-U100: first metabolomics-based IVD test for allograft rejection diagnosis after kidney transplantation

2017

Collaboration with Oxford University to develop a multiple sclerosis diagnostic test

2016

1 million performed analyses

2016

Numares completes another financing round

2015

Launch of CE-marked IVD test AXINON^® lipoFIT^®-S100 for comprehensive NMR-based lipoprotein profiling

2014

600,000 performed analyses

2014

Successful completion of studies on kidney transplantation

2014

Cooperation with a German laboratory network: commissioning a test system for lipoprotein profiling

2013

200,000 performed analyses

2013

Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling

2013

Successful certification of numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)

2010

100,000 performed analyses

2009

Certification as per EN ISO 13485:2003

2005

Measurements in large studies, such as GRAPHIC and KORA

2004

First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)

Leadership

“AXINON^® vereint Flexibilität, Personalisierung und Hightech - ideale Voraussetzungen, um diese Diagnostik für alle zugänglich zu machen, die Gesundheitskosten zu minimieren und den Shareholder Value zu maximieren. ”

Florian Voss

Vorstand, CEO

"Our AXINON^® platform combines software engineering and AI/machine learning with NMR technology. This gives us the rare opportunity to address multiple metabolic markers, constellations of markers and, ultimately, diseases, using a single technology platform. Because of this capability, the AXINON^® platform provides a wide range of applications from life sciences to routine diagnostics to personalized diagnostics."

Andreas Wolf

CTO

"Obwohl unser AXINON^® IVD-System nur minimale Bedienereingriffe erfordert, ist es unser Anspruch, unsere Kunden mit dem besten Support zu begleiten - über die Installation und Wartung hinaus."

Dr. Lutz Niggl

Leiter Service

Supervisory Board

Volker Pfahlert, PhD

- Chairman, Supervisory Board
- Former CEO, Numares Health
- Previously with Roche and McKinsey

Kathy L. Bates, MBA

- Former Sr. Director of Partnership, Mayo Clinic
- Previously with OncoSpire Genomics and Roche

Dr. Gregory F. Heath, PhD

- Former General Manager of Diagnostics, Illumina, Inc.
- Former Sr. Vice President of Molecular Business, Roche Diagnostics

Jorg Neermann, PhD

- Former General Manager of Diagnostics, Illumina, Inc.
- Former Sr. Vice President of Molecular Business, Roche Diagnostics

Gerhard Ries, PhD

- CEO and Co-Founder, Kineo Finance
- Former Managing Partner and Co-Founder, BioMedPartners
- Former Business Development Manager, Novartis and McKinsey

Helge Luetzen

- Sr. Investment Manager, Mayfair

Name	Zweck	Ablauf	Typ	Anbieter
_gcl_au	Wird von Google AdSense zum Experimentieren mit Werbungseffizienz auf Webseiten verwendet.	3 Monate	HTML	Google
AMP_TOKEN	Enthält ein Token, das verwendet werden kann, um eine Client-ID vom AMP-Client-ID-Service abzurufen. Andere mögliche Werte zeigen Opt-out, Anfrage im Gange oder einen Fehler beim Abrufen einer Client-ID vom AMP Client ID Service an.	1 Jahr	HTML	Google
_dc_gtm_--property-id--	Wird von DoubleClick (Google Tag Manager) verwendet, um die Besucher nach Alter, Geschlecht oder Interessen zu identifizieren.	2 Jahre	HTML	Google

“AXINON® vereint Flexibilität, Personalisierung und Hightech - ideale Voraussetzungen, um diese Diagnostik für alle zugänglich zu machen, die Gesundheitskosten zu minimieren und den Shareholder Value zu maximieren. ”

Florian Voss

Andreas Wolf

"Obwohl unser AXINON® IVD-System nur minimale Bedienereingriffe erfordert, ist es unser Anspruch, unsere Kunden mit dem besten Support zu begleiten - über die Installation und Wartung hinaus."

Dr. Lutz Niggl

Volker Pfahlert, PhD

Kathy L. Bates, MBA

Dr. Gregory F. Heath, PhD

Jorg Neermann, PhD

Gerhard Ries, PhD

Helge Luetzen

“AXINON^® vereint Flexibilität, Personalisierung und Hightech - ideale Voraussetzungen, um diese Diagnostik für alle zugänglich zu machen, die Gesundheitskosten zu minimieren und den Shareholder Value zu maximieren. ”

"Obwohl unser AXINON^® IVD-System nur minimale Bedienereingriffe erfordert, ist es unser Anspruch, unsere Kunden mit dem besten Support zu begleiten - über die Installation und Wartung hinaus."